TITLE

Circulating H3K27 Methylated Nucleosome plasma concentration: a synergistic information with ctDNA Molecular Profiling

AUTHORS INFORMATION

Emmanuel GROLLEAU [1,2,†], Julie CANDIRACCI [3,†], Gaelle LESCUYER [1,4,5,6], David BARTHELEMY [1,4,5,6], Nazim BENZERDJEB [1,7], Christine HAON [1,5,6], Florence GEIGUER [1,4,5,6], Margaux RAFFIN [1,4,5,6], Nathalie HARDAT [3], Julie BALANDIER [1,4,5,6], Rémi RABEUF [3], Lara CHALABREYSSE [7], Anne-Sophie WOZNY [5,6,8], Guillaume ROMMELAERE [3], Claire RODRIGUEZ-LAFRASSE [5,6,8], Fabien SUBTIL [9], Sébastien COURAUD [1,2], Marielle HERZOG [3], Lea PAYEN-GAY [1,4,5,6,*]

[1] Center for Innovation in Cancerology of Lyon (CICLY) EA 3738, Faculty of Medicine and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France.

[2] Pulmonology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.

[3] Belgian Volition SRL, Parc Scientifique Créalys; 5032 Isnes, Belgium.

[4] Institut of Pharmaceutical and Biological Sciences (ISPB), Claude Bernard Lyon I, 69373 Lyon, France.

[5] Department of Biochemistry and Molecular Biology, Lyon-Sud Hospital, Hospices Civils de Lyon, 69495 Pierre-Bénite, France.

[6] Circulating Cancer (CIRCAN) Program, Hospices Civils de Lyon, Cancer Institute, 69495 Pierre-Bénite, France.

[7] University of Lyon, Claude Bernard University, pathology department, Hospices Civils de Lyon; Pierre-Bénite, France.

[8] Cellular and Molecular Radiobiology Laboratory UMR CNRS5822/IP2I, Faculty of Medicine

and Maieutic Lyon Sud, Claude Bernard University Lyon I, 69921 Oullins, France.

[9] University of Lyon, Claude Bernard University, statistic department, Hospices Civils de Lyon;

Pierre-Bénite, France.

[†] Emmanuel Grolleau and Julie Candiracci have contributed equally to this work

* Correspondence: Léa Payen-Gay, lea.payen-gay@chu-lyon.fr

ABSTRACT

Background: Molecular profiling of circulating tumor DNA (ctDNA) is a helpful tool for cancer treatment indication or for the early detection of relapse. A subset of patients with advanced lung adenocarcinoma cancers (NSCLC)can be cured by immunotherapy, radiotherapy, and/or chemotherapy combined regimens, or targeted therapies depending on their ctDNA molecular profile. However, clinical interpretation of ctDNA negative result remains challenging. Cell-free DNA (cfDNA) in association with nucleosomes are released into the bloodstream upon cell death therefore the characterization of both may provide useful information for patient management., Dysregulations of epigenetic modifications, such as histone methylation, are found to play a key role in tumorigenesis of different cancers. However, the concentration of circulating nucleosomes in blood, as a biomarker of the contributive value of ctDNA molecular profiling in patient management at diagnosis or during patient follow-up has not previously been investigated.

Results: Significantly elevated concentrations of H3K27Me3-nucleosomes were found in plasmas at diagnosis and during the follow-up of NSCLC patients compared to healthy donors (median: 24ng/ml; 16.9ng/ml vs 8ng/ml, p-value<0.0001, respectively). Interestingly, by combining H3K27Me3 level and ctDNA molecular profile, we found that 25.5% of the patients

had high levels of H3K27Me3 (above cut-off level at 22.5 ng/ml) and no somatic alteration detected at diagnosis. This strongly supports the presence of non-mutated ctDNA in the corresponding plasma. During patient follow-up, H3K27Me3 level was lower in ctDNA-negative group compared to ctDNA-positive group (medianctDNA- = 13.4 ng/mL vs medianctDNA+ = 26.1 ng/mL, respectively, p_value<0.0001). In 41.8% of the samples, no somatic mutation and low level of H3K27Me3-nucleosomes were observed suggesting molecular indicator of treatment response. In contrast, high H3K27Me3-nucleosome level was found in 15.1% of the sample despite no somatic mutations being detected allowing the identification of disease progression from 43.1% to 58.2% over molecular profiling alone.

Conclusion:

Measuring H3K27Me3-nucleosome levels in combination with ctDNA molecular profiling may not only improve confidence in the negative molecular result in cfDNA in lung cancer at diagnosis, it may also be a promising biomarker for Molecular Residual Disease (MRD) monitoring during and/or after treatment.

Keywords

NSCLC, epigenetics, histone PTM, H3K27Me3-nucleosome, ctDNA, liquid biopsy, biomarkers, MRD

BACKGROUND

Nucleosomes are small fragments of chromosomes released into the blood during cell death and consist of a histone octamer core with DNA wrapped around it. Interestingly, the size distribution of the DNA released into circulation (cell free DNA (cfDNA)) corresponds to nucleosomes ($\approx$ 147bp) or chromatosome (nucleosome + DNA linker; $\approx$ 167bp) (1). CfDNA released into the blood following cell death exists in nucleosomal structures and encapsulated

in extracellular vesicles which protects them from degradation rather as free DNA fragments

(2, 3, 4, 5). In patients with cancer, cfDNA/nucleosomes are released from tumor cells and may

harbor tumor DNA (ctDNA) and a variety of histone of post-translational modifications (PTMs)

(6, 7).

Histone proteins PTMs such as methylation, acetylation, phosphorylation or citrullination

regulate most of DNA-templated processes, including replication, transcription and repair.

They function as platforms for the recruitment of specific effector proteins, such as

transcriptional regulators or chromatin remodelers (8). They can also change the chromatin

structure by disrupting the electrical charges in the histone residues and thus modulate

accessibility to the DNA (9, 10). Histone methylation is dynamically controlled by various

lysine histone demethylase (HDM) and histone methyltransferase (HMT) enzymes that remove

or add the methyl group(s) from the lysine residues. Mis-regulation of the HDM and HMT leads

to aberrant levels of histone methylation and have been associated with a variety of cancer types

including breast, prostate, lung and brain cancers (11). For example, the HMT enzyme,

Enhancer of Zeste Homolog (EZH2), the catalytic subunit of polycomb repressive complex 2

(PRC2), responsible for the trimethylation of histone H3 at lysine 27 (H3K27Me3), has been

reported to be up regulated in cancer (12, 13). Its overexpression also correlates with breast

cancer aggressiveness and poor prognosis (14). In parallel, H3K27Me3 levels are associated

with transcriptional repression and have been reported to play an important role in the

development and progression of several cancers including lung cancer (15, 16, 17). EZH2-

catalyzed H3K27Me3 is also a master regulator of epithelial mesenchymal transition (EMT),

an early cellular reprogramming event to facilitate the initial steps of the metastatic cascade

(18, 19, 20). EZH2 levels are impaired in tumor angiogenesis and associated with drug

resistance phenotype in multiple cancers (21, 22).

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI), such as Osimertinib and Gefitinib, have only been proven to be beneficial for patients with EGFR sensitizing genetic alterations in lung cancer (23). Recently, it had been shown that EZH2 inhibitors could sensitize *in vitro* EGFR wild-type cells to Gefitinib (24). EZH2 is highly expressed in Non-Small Cell Lung Cancer (NSCLC) and is associated with poor prognosis in patients with lung adenocarcinoma. Therefore, targeting H3K27Me3 via EZH2 is a promising cancer therapy. Tazemestostat, is the only EZH2 inhibitor approved by FDA for adults and pediatric patients aged 16 years and older. Currently, there are several ongoing clinical trials for drugs targeting EZH2 in different cancer types (25).

Combined ctDNA molecular testing to analyze circulating nucleosomes and their histone PTMs before and after patient's treatment could provide a wider view of the genetic and the epigenetic landscape of a tumor and response to treatment. This would also enable minimal residual disease (MRD) assessment. Therefore, we conducted this retrospective, non-interventional study to i) to determine, at diagnosis, the level of circulating nucleosomes containing methylated histone residues, especially H3K27Me3-nucleosomes as potential biomarkers in patients with stage IV NSCLC; ii) to assess, during treatment, the dynamic levels of H3K27Me3-nucleosomes in NSCLC with different mutated ctDNA status to evaluate MRD to drive the choice of the following treatment line. We studied the ctDNA analysis association with nucleosome biomarkers in two independent cohorts of NSCLC patients: a first one at diagnosis before any treatment, a second one undergoing treatment including chemotherapy, combined or not with immunotherapy, or targeted therapy. Nucleosome measurements were performed on the same sample as the molecular ctDNA testing on the routine setting. This strengthens the accuracy of using biomarkers in patient management of NSCLC.

For the first time, we report a high level of circulating H3K27Me3-nucleosomes in NSCLC samples compared to healthy samples and the potential benefit of the combination of

information generated by the measurement of H3K27Me3-nucleosome levels in association

with the molecular ctDNA profile at diagnosis for the patient management. We also highlight

the putative role of circulating H3K27Me3-nucleosomes as blood-based biomarkers for

quantifying the MRD to monitor NSCLC patients during treatment.

RESULTS

High levels of circulating H3K27Me3-nucleosomes are observed in NSCLC samples at

diagnosis

The concentration of circulating nucleosomes with specific methylated marks H3K27Me3-,

H3K36Me3-, H3K9Me3- and H3K4Me2- were measured using chemiluminescent Nu.Q$^{®}$

immunoassays in NSCLC samples (training set (T) n_T = 203; validation set (V) n_V = 116) and

compared to healthy samples (n_T = 100; n_V = 101). In both sets, we observed significantly higher

circulating H3K27Me3-, H3K36Me3- or H3K9Me3-nucleosome levels in NSCLC samples

compared to healthy (median$_T$: 22.7 ng/mL *vs* 6.1 ng/mL; 21.8 ng/mL *vs* 11.8 ng/mL; 15.2

ng/mL *vs* 5.7 ng/mL, respectively; *p*-value < 0.0001 for each and median$_V$: 28.3 ng/mL vs 9.6

ng/mL; 24.0 ng/mL vs 10.0 ng/mL; 20.4 ng/mL vs 7.5 ng/mL, respectively; *p*-value < 0.0001

for each) (Fig. 1A, B). A lower difference was observed for H3K4Me2-nucleosome levels

between NSCLC and healthy samples (median$_T$: 11.3 ng/mL *vs* 10.6 ng/mL and median$_V$ = 12.4

ng/mL *vs* 11.2 ng/mL, respectively; *p*-value < 0.01 for each), with a very small magnitude

(Table S1). The highest change observed between the medians of tumor and healthy samples

was observed for the level of H3K27Me3-nucleosomes with a fold change of 3.7 and 2.9 in

training and validation sets, respectively (Table S1). This marker also showed the best area

under the ROC (receiving operating characteristics) curve (AUC) with a value of 0.92 (95%

CI: 0.89 - 0.95) and 0.88 (95% CI: 0.84 - 0.93) corresponding to the training and validation sets

analysis (Fig. 1C, D and Fig. S1A, B). The sensitivity of the H3K27Me3 assay reached 69.5%

(95% CI: 61.8% - 74.5%) at 95% specificity in the training set. These clinical performances

were confirmed in the validation set where the sensitivity reached 68.7% (95% IC: 59.7% -

76.5%%) at 95% specificity (Fig. 1C, D and Table S2A, B).

H3K27Me3-nucleosome levels correlate with cfDNA quantity and percentage of

Mutational Allele Fraction (MAF) at diagnosis

Circulating nucleosomes containing the methylated histone marks and quantity of cfDNA or

the percentage of mutated allele MAF correlated well (Fig. 2). The training and validation sets

were combined into one whole cohort to increase the number of samples per group for better

accuracy (n_{NSCLC} = 319; $n_{HEALTHY}$ = 201). At diagnosis, patients with NSCLC showed a strong

positive correlation between the levels of cfDNA and H3K27Me3-,H3K36Me3-, or H3K9Me3-

nucleosome (r = 0.78; 0.66 and 0.75, respectively, p-value < 0.0001) and a moderate correlation

with H3K4Me2-nucleosome (r = 0.53; p-value < 0.0001). The percentage of MAF for genomic

somatic alterations in plasma samples was defined using the ratio absolute count of read

between the reference and mutated forms. All H3K27Me3-, H3K36Me3-, H3K9Me3-

,H3K4Me2-nucleosome levels and cfDNA concentration showed a weak, but statistically

highly significant correlation coefficient with the percentage of MAF (r = 0.33; 0.31; 0.32 and

0.21, respectively; p-value < 0.0001 and r = 0.28; p-value < 0.001, respectively) (Fig. 2).

H3K27Me3 expression level in normal and adenocarcinoma tissue.

The immunohistochemical investigation of tissue microarrays (TMAs) of normal pneumocytes

(n = 18) showed moderate to high H3K27Me3 expression level in 83% of cases (Fig. 3A). In

the alveolar region (parenchyma) of normal lung tissue, where air and blood are brought in

closed proximity over a large surface, the barrier between air and blood consists of a continuous

alveolar epithelium (a mosaic of type I and type II alveolar epithelial cells), a continuous

capillary endothelium and the connective tissue layer in-between, as showed in Fig. 3A. In contrast in tumoral tissue (n = 50, two cores per patient), remodeling structural events occurred (Fig. 3B, C, D). We observed i) weak H3K27Me3 expression level in 42% of cases (Fig. 3B), ii) moderate expression level in 37% of cases (Fig. 3C), and iii) high expression level in 21% of cases (Fig. 3D). TMAs of lung adenocarcinoma showed heterogeneous H3K27Me3 expression levels within the same patient demonstrating an intra-tumoral heterogeneity (data not shown). The analysis of H3K27Me3 expression as a function of grade showed that the expression of H3K27Me3 is associated with the tumor grade. Higher H3K27Me3 expression was observed in tumor grades 2 and 3 (Fig. 3E). In contrast, H3K27Me3 expression heterogeneity was not associated with the tumor grade.

Relevant combined information from circulating H3K27Me3-nucleosome levels and ctDNA molecular profile at diagnosis

As H3K27Me3-nucleosome level is high in NSCLC samples but showed a low, although significant correlation, with MAF; we asked if H3K27Me3 levels could bring additional information relative to the potential presence of circulating tumor material or process. To address this question, we first defined the upper limit of the reference interval of H3K27Me3-nucleosomes in a healthy population. As the distribution of the training and validation sets were similar (Fig. S2), we combined the two sets of samples into a global and homogenous healthy cohort (n = 201) in which no outlier was identified using both the D/R ratio and ROUT methods. The upper limit of the reference interval including 95% of this population was calculated at 18.4 ng/mL (SD = 4.07). Then, we defined a cut-off at 22.5 ng/mL (18.4+1SD) ensuring 100% specificity in both training and validation sets. In the whole NSCLC cohort (n = 318), 53.1% of the patients (n = 169) showed H3K27Me3-nucleosome levels above the cut-off (Fig. 4A). The presence or absence of somatic alterations was reported on the same plasma samples based on DNAseq next-generation sequencing (NGS) analysis (the comprehensive panel contains the

major 78 oncodrivers known in NSCLC). In the whole NSCLC cohort, there were 41.2% samples for which at least one somatic alteration or copy number variation (CNV) was identified, referred to hereafter as ctDNA positive sample (ctDNA+; n = 131) and 58.8% of patients for whom no genetic somatic alteration was found and defined as ctDNA negative (ctDNA-; n = 187) hereafter. The level of H3K27Me3-nucleosomes is significantly higher in ctDNA+ group compared to ctDNA- group (median = 33.9 ng/mL vs 18.5 ng/mL; p-value < 0.001) and compared to healthy group (median = 33.9 ng/mL vs 8.0 ng/mL; p-value < 0.0001) (Fig. 4B). H3K27Me3-nucleosome levels were also higher in the ctDNA- group compared to healthy group (median = 18.5 ng/mL vs 8.0 ng/mL; p-value < 0.0001).

Based on these observations, we compared the tumor mutation burden defined by the ctDNA status of the samples and the H3K27Me3-nucleosome concentrations in a decision tree model (Fig. 5). We sub-classified the samples based on their ctDNA status (ctDNA- or ctDNA+) and based on their H3K27Me3-nucleosome levels defined as H3K27Me3 positive (H3K27Me3+) or H3K27Me3 negative (H3K27Me3-) depending on whether H3K27Me3-nucleosome levels were above or below the defined cut-off at 22.5 ng/mL. We observed that: i) 33.3% of samples were double negative for ctDNA and H3K27Me3; ii) 25.5% of samples were negative for somatic alteration but had a high level of H3K27Me3-nucleosomes; iii) 13.5% samples had a low level of H3K27Me3, even if somatic alterations had been detected; iv) 27.7 % samples were found to be positive for both ctDNA and H3K27me3-nucleosomes (Fig. 5).

High level of circulating H3K27Me3-nucleosomes observed in NSCLC samples during treatment is more pronounced in presence of mutated ctDNA.

Based on the results observed at diagnosis, we decided to focus our analysis of NSCLC samples collected during patient treatment on H3K27Me3 only to evaluate its level change across the treatment. We assessed the concentration of circulating H3K27Me3-nucleosomes in NSCLC

samples (n = 304) in routine settings and compared to healthy samples (n = 201). A highly

significant increase was observed in NSCLC compared to healthy samples (median = 16.9

ng/mL vs. 8 ng/mL, respectively; p-value < 0.0001) (Fig. 6A). In this NSCLC population, the

H3K27Me3-nucleosome levels were lower than samples collected at diagnosis (median$_\text{DURING}$

$_\text{TREATMENT}$ = 16.9 ng/mL vs median$_\text{AT DIAGNOSIS}$ = 24 ng/mL p-value < 0.0001).

The molecular profiles of these NSCLC samples were conducted by NGS analyses. In 43.1%

of the samples (n =131), at least one mutation among the 78 screened genes was detected,

demonstrating the presence of ctDNA in plasma samples. Then, we compared the circulating

H3K27Me3-nucleosome levels in positive and negative ctDNA samples (ctDNA+, ctDNA-)

collected during the treatment. The level of circulating H3K27Me3-nucleosomes was lower in

the ctDNA-negative group compared to ctDNA-positive group (median$_\text{ctDNA-}$ = 13.4 ng/mL vs

median$_\text{ctDNA+}$ = 26.1 ng/mL, respectively, p-value < 0.0001) (Fig. 6B). A greater heterogeneity

of H3K27Me3-nucleosome levels was observed in presence of somatic alteration, 55% of

samples were found above the H3K27Me3-nucleosomes cut-off in the ctDNA+ group, whereas

only 26.6% of the samples were above in the ctDNA- group (Fig. 6B). The clinical performance

was then evaluated on the whole cohort (in grey), on the ctDNA- (dotted line) and ctDNA+ (in

black) sub-groups in comparison to the healthy samples (Fig. 6C, Table S3). We found that the

discrimination of NSCLC samples was improved in ctDNA+ sub-group with an AUC of 0.87

compared to 0.74 for ctDNA- sub-group and 0.79 for the whole cohort respectively; p-value <

0.0001) (Fig. 6C, D).

Additive value of both biomarkers: H3K27Me3-nucleosomes and ctDNA

After sub-grouping of NSCLC samples collected during treatment into ctDNA- and ctDNA+

classification; samples were further classified based on their level of circulating H3K27Me3-

nucleosomes below or above the cut-off at 22.5 ng/mL, as H3K27Me3-negative (H3K27Me3-

) or H3K27Me3-positive (H3K27Me3+) and organized in four classes described in a decision

tree (Fig. 7A). We observed i) 41.8% of samples are double negative for the ctDNA and

circulating H3K27Me3-nucleosome levels (ctDNA- H3K27Me3-); ii) 15.1% of samples are

negative for somatic alteration but positive for circulating H3K27Me3-nucleosomes (ctDNA-

H3K27Me3+); iii) 19.4% of samples had a level of circulating H3K27Me3-nucleosomes below

22.5 ng/mL, even when somatic alterations had been detected (ctDNA+ H3K27Me3-); iv)

23.7% of samples were found to be positive for both ctDNA and circulating H3K27Me3-

nucleosome levels (ctDNA+ H3K27Me3+).

High circulating H3K27Me3-nucleosome levels are preferentially associated with TP53

mutations during treatment.

In ctDNA+ group, levels of circulating H3K27Me3-nucleosomes were compared based on the

mutation status of three major oncodrivers of interest: EGFR, KRAS and TP53. Mutational

status in the corresponding sub-groups was annotated as positive (+) when at least one mutation

was detected and negative (-) when no mutation was detected (Fig 7). In parallel of the tendency

of association found at diagnosis (data not shown), significant increase of circulating

H3K27Me3-nucleosome levels was observed in TP53+ (n = 72) sub-group compared to TP53-

(n = 59) sub-group (median$_{TP53+}$ = 36.9 ng/mL vs median$_{TP53-}$ = 19.2 ng/mL; p-value < 0.05) (Fig.

8 A-B). No difference was observed in comparisons between EGFR+ versus EGFR- neither

KRAS+ versus KRAS- sub-groups (median$_{EGFR+}$ = 21.8 ng/mL vs median$_{EGFR-}$ = 36.3 ng/mL; p-

value = 0.22; median$_{KRAS+}$ = 14.8 ng/mL vs median$_{KRAS-}$ = 26.7 ng/mL; p-value = 0.50) (Fig. 8

A-B).

DISCUSSION

Patient management with NSCLC is based on histopathological evaluation completed with

protein and molecular biomarkers for determining the optimal treatment. Tumor tissue-based

molecular testing has demonstrated its utility to assess patients for the recommended

biomarkers but remains challenging due to tissue invasive sampling, DNA quantity availability

and heterogeneity, and inadequacy of repeated testing (26). In contrast, genomic somatic testing

of oncodrivers through liquid biopsy has emerged as a key strategy for managing patients that

are diagnosed with an advanced NSCLC and can be used both at diagnosis to define first-line

therapy and throughout patient follow-up to identify the emergence of resistant mechanisms.

Therefore, although tissue biopsy remains the reference standard for cancer diagnosis and

patient management, when combined with plasma-based molecular profiling, the patient

standard of care is improved by approximately 11 to 20% (27, 28, 29). In contrast to tissue

biopsies, plasma testing can be easily repeated serially to monitor response and may allow

detection of minimal residual disease prior to ct-scan or clinical progression. It also reduces

invasiveness and costs. In consequence, it is more compliant for patients. Despite the high

clinical specificity of ctDNA, physicians often face a high non-contributive detection rate of

preoperative mutated plasma ctDNA, around 24% to 85% in the overall population of lung

cancers associated with stage in routine settings (30, 31, 32). CtDNA was detected after

treatment in 64.3% of patients who had obvious clinical recurrence (33). Moreover, a study

conducted by Chaudhuri et al., showed that disease recurrence in ctDNA negative population

happened in 6% of the post-operative population of NSCLC patients (34). So currently, the

interpretation of an undetectable ctDNA is still a significant limitation in clinical indication.

Other circulating biomarkers may complement ctDNA molecular testing. Circulating

nucleosome as the carrier of genetic and epigenetic information and genetic aberrations could

be one of these. In addition, thanks to the low volumes required for the nucleosome Nu.Q®

immunoassay, it is easy to add it at the plasma molecular profiling testing on the same plasma

sample. In this study, we focused on circulating H3K27Me3-nucleosome levels in NSCLC patients at diagnosis or during their treatment, and the combined contributive information to molecular profiling of circulating H3K27Me3-nucleosomes.

TMA analysis showed that H3K27Me3 was detected in the nucleus of normal adjacent cells and adenocarcinoma cells. Histone modification is a dynamic process as demonstrated recently by FRET (fluorescence resonance energy transfer) biosensor-based technique in cancer living cells (35). Unlike H3K9Me3 that is always associated with silenced chromatin regions, H3K27Me3 mark is found in bivalent domains associated with gene repression but still allow these genes to be activated (36). The repression was not randomly distributed within the genome but enriched in inactive topologically associated domains (TADs) with low expression of genes involved in proliferation (37, 38). As described for genetic clonality profiling and PD-L1 (programmed death ligand 1) tissue expression, we observed intra- and inter-tumoral heterogeneity in adenocarcinomas (39). Interestingly, the frequency of high expression of H3K27Me3 was larger in grade 3 adenocarcinoma compared to grade 2 and grade 1 suggesting that in NSCLC, like in thyroid cancer or invasive phenotype of melanoma, H3K27Me3 overexpression could be positively associated with tumor aggressiveness (40, 41). Cellular plasticity and tumor cells dedifferentiation is commonly observed in various types of malignancies and is described to be associated with increased tumor cell invasiveness and drug resistance. We can speculate that the association between H3K27Me3 level and tumor aggressiveness could be linked with its role in this loss of differentiation of tumor cells (42, 43, 44). At diagnosis, circulating H3K27Me3-nucleosome levels are significantly higher in NSCLC patients compared to healthy donors. In contrast to tissue observation, this analysis of circulating H3K27Me3-nucleosomes reflects the release of nucleosomes into the blood following cell death and high cell turnover occurring in cancer (45, 46, 47).

To discuss the advantage of the quantification of H3K27Me3-nucleosomes in clinical settings,

we had to establish the normality range into healthy population using similar methodology as

other tumoral biomarkers such as CYFRA21.1 and CA125. For doing that, we first determined

the upper limit of the reference interval of H3K27Me3-nucleosomes in a healthy population

and determined the threshold of positivity at 22.5 ng/mL ensuring 100% specificity in both

training and validation sets. Increased H3K27Me3-nucleosome levels observed in NSCLC

patients was even more pronounced in patients who have somatic alterations and was logically

positively associated to the cfDNA concentration as its carrier. Somatic mutations were found

in 41.2% of analyzed samples. 27.7% of the samples were positive for both ctDNA and

circulating H3K27Me3-nucleosomes pointing to putative epigenetic and mutational burden

processes, while in 13.5% samples only somatic alterations were detected demonstrating the

presence of tumoral material in blood but a low level of H3K27Me3-nucleosome which might

suggest a low-grade tumor or epigenetic changes compared to normal cells as supported by the

TMA analysis performed.

Besides, one fourth of patients (25.5%) had a high H3K27Me3-nucleosome levels even if no

somatic alteration were detected in plasma. This is indicative of tumoral DNA release into blood

despite absence of somatic alteration detected, indicating somatic mutation not covered by the

comprehensive panel of genes used in the customized NGS assay and potentially a high-grade

cancer. We can hypothesize that most likely nucleosome and its associated DNA came from

cancer cells but from a genomic region that did not have a cancerous mutation. Those samples

could be considered as true ctDNA negative for the main oncodriver alterations. In the opposite,

33.3% of the samples were negative for both ctDNA and H3K27Me3-nucleosome level

indicating no or very few tumoral material released into blood. In this case, a re-biopsy will be

probably required for those patients at diagnosis until additional cancer biomarkers are

identified. Altogether, these results at diagnosis showed that by combining circulating

H3K27Me3-nucleosome levels with genomic testing, we can increase the contributing information of ctDNA sequencing by 25.5% to help interpret negative ctDNA results. In addition, high level of H3K27Me3-nucleosomes in half of the cases (52%) could be used as a biomarker to monitor patients during follow-up.

During patient's treatment, high levels of circulating H3K27Me3-nucleosomes were still observed in NSCLC samples especially in presence of mutated ctDNA. Nevertheless, we can note that despite being still high, the H3K27Me3-nucleosome levels in the ctDNA negative group were closer to the one observed in the healthy group with 61.2% of the samples below the cut-off. As the study was conducted on two independent cohorts at diagnosis and during treatment, it was not possible to make a direct comparison. But Holdenrieder and al. described that in patients with advanced lung cancers, levels of circulating nucleosomes at diagnosis were significantly lower in patients who responded to chemotherapy, suggesting that nucleosome could be a potential predictive biomarker (48). When combining both ctDNA sequencing and H3K27Me3-nucleosome measurements, we observed nearly 42% of the samples negative both ctDNA and H3K27Me3-nucleosomes suggesting no detection of tumoral material and a potential positive evolution of the disease. First-line treatment should be continued, and the next follow-up may be spaced out in time (Fig. 7B). In 15% of the samples, no somatic mutation was found but a high level of circulating H3K27Me3-nucleosomes was detected. This could illustrate a progression of the disease in absence of acquisition of somatic mutation, or no alteration covered by the NGS comprehensive gene panel. A change in the treatment to classic second line therapy may be considered (Fig. 7B). These results could also suggest that a combined therapy with EZH2-inhibitor might be appropriate. More clinical data on EZH2 inhibitor performances in NSCLC are required to confirm or not this option. Somatic mutations have been detected in the remaining 43% of the samples associated with a high level of H3K27Me3-nucleosomes (23.7%) or not (19.4%) demonstrating a progression of the cancer

and the need to change the treatment (Fig. 7B). Importantly, when the level of H3K27Me3-

nucleosomes is considered with ctDNA there was an increased identification of disease

progression from 42 to 58% of patients. In addition to the potential benefit to combine

H3K27Me3-nucleosomes and ctDNA analysis at diagnosis to ascertain a true negative ctDNA

results, we propose that H3K27Me3-nucleosomes could also be a good potential biomarker to

detect minimal residual disease and to monitor response during disease progression. Further

studies would be required to validate the potential of circulating H3K27Me3-nucleosomes as

biomarker for NSCLC patient follow-up. When validated, we could consider implementing the

measurement of H3K27Me3-nucleosomes before molecular profiling analysis for an improved

patient care and a more cost-efficient health care system. Indeed, if during post-treatment, the

patient is well with normal scan images and low H3K27Me3-nucleosomes levels, ctDNA

analysis could be postponed. In contrast, high level of H3K27Me3-nucleosomes levels should

trigger a quicker ctDNA analysis and therapeutic decision.

In French population, the frequency of tissue somatic alterations reported in patient with

NSCLC is 11% in *EGFR*, 1% in *HER2*, 29% in *KRAS* 2% in *BRAF*, and 2% *PIK3CA (49)*. In

our study, the molecular status was not fully associated with the H3K27Me3-nucleosome

concentrations. Nevertheless, the TP53 status, especially during progression, seems to be

correlated with the H3K27Me3-nucleosome concentration. 40% TP53 somatic alterations are

reported in NSCL (50, 51, 52). This detection is an indicator of a poor prognosis in patients

with NSCLC. In advanced NSCLC patients treated with nivolumab, with or without CTLA-4

blocker ipilimumab, or pembrolizumab, the median overall survival in the TP53-mutated group

was 18.1 months vs 8.1 in the TP53-wild-type group. This strongly indicated that TP53 status

might be potential predictor of immunotherapy response (53). These TP53 mutations may differ

according to different pathological types and clinical stages and are often detectable during

progression or in aggressive grade. These findings agreed with the higher level of H3K27Me3-

nucleosome into TP53 mutated samples observed in our cohorts. In this report, the H3K27Me3-
nucleosome concentration was not statistically different according to the EGFR and KRAS
status and must be addressed in a wider cohort.

CONCLUSIONS

Using a simple and low-cost H3K27Me3-nucleosomes immunoassay to complete the molecular

exploration of ctDNA could greatly improve confidence in the negative molecular results at

diagnosis. This may allow to reduce re-biopsy invasive acts. High levels of H3K27Me3-

nucleosomes could allow physicians to detect MRD in NSCLC patients at defined intervals of

treatment and recovery to incorporate analysis of evolving molecular landscapes during

treatment. These data should be confirmed in a longitudinal study where NSCLC patients will

be followed from diagnostics to recovery or relapse.

METHODS

Study Population:

Patients were recruited from the pulmonology department at Lyon University Hospital from

2015 to 2022. K2-EDTA plasma heathy samples were provided by the French agency named

"Etablissement Français du Sang" (Etude RNIPH 22-5065 NUCLEO_CIRCAN avis CSE n°22-

5065). Inclusion criteria were: age over 18 years old with histologically proven NSCLC cancer.

For each sample, medical data were collected through a mandatory prescription sheet attached

to each sample and edited by the prescribing physician. K2-EDTA plasma samples from 319

patients at diagnosis and from 309 independent patients under treatment, defined by a clinical

or CT-scan modification during their treatment were analyzed.

CfDNA Collection:

Total EDTA blood samples were centrifuged for 10 min at 1600 g. The supernatant was then

centrifuged at 6000 g for 10 min, and the resulting plasma was stored at −80 °C until cfDNA

extraction and molecular analyses (54). CfDNA was extracted using the QIAamp Circulating

Nucleic Acid Kit (Qiagen, Valencia, CA, USA, Cat No 55114), with a Qiagen vacuum manifold

following the manufacturers' instructions. CfDNA samples were quantified using a Qubit™ 4

Fluorometer (Invitrogen™, Cat No Q33238, Carlsbad CA, 92008, United States) with the

Qubit™ dsDNA HS Assay Kit (Invitrogen™, Cat No 32854).

Library Preparation for DNA Sequencing:

For custom-validated NGS library preparation, 10 – 100 ng cfDNA were used, using a custom

capture-based technology provided by SOPHiA GENECTICS (Lausanne, Switzerland) and

performed according to the manufacturer's instructions (55, 56, 57). The custom panel covered

78 genes involved in cancer (such as *EGFR*, *TP53* or *KRAS*). The libraries were sequenced on

NextSeq 550 (Illumina technology, San Diego, CA 92122) in 2 × 150 paired-end runs. The

subsequent Variant Call Files were subjected to cross-sample background filtering, with

potential artefacts removed below 3 standard deviations of the mean background noise for each

position. The bioinformatics was performed using the SOPHIA DDM™ platform.

Nu.Q® ImmunoAssays:

Four nucleosome structures were measured using Nu.Q® prototype Immunoassays: Nu.Q®

H3K27Me3, Nu.Q® H3K36Me3, Nu.Q® H3K9Me3, Nu.Q® H3K4Me2 (Belgian Volition SRL,

Isnes, Belgium) according to the manufacturer's instruction. Briefly, these sandwich

immunoassays are based on magnetic beads and chemiluminescence technology and are

performed on the IDS-i10 automated immunoanalyzer system (Immunodiagnostic Systems Ltd

(IDS), UK). 50 μL of K2-EDTA plasma (same as for the DNA sequencing) are incubated with

acridinium ester labeled anti-nucleosome antibody. Then, magnetic particle beads, coated with

the corresponding monoclonal anti-histone modification capture antibody (i.e., anti-histone

H3K27Me3, anti-histone H3K36Me3, anti-histone H3K9Me3, or anti-histone H3K4Me2,

respectively), are added. Finally, after a wash step, trigger solutions are added, and the light

emitted by the acridinium ester is measured by the luminometer system. The results are

expressed in relative light unit (RLU) and the concentrations are extrapolated using a four-

parameter logistic regression of a reference standard curve. All samples are analyzed in

simplicate.

Tissue microarray (TMA):

Two TMAs were purchased from the company TissueArray.com. The first TMA corresponds

to 100 cores of 50 cases (2 cores by case) of lung adenocarcinoma (BC04022a), while the

second TMA contains 18 cases of squamous cell carcinoma, matched with adjacent normal lung

tissue and cancer adjacent tissue per case (LC10014a).

The immunohistochemical analysis was performed with an automated immunostainer (BOND).

Briefly, formalin-fixed paraffin-embedded 4-µm-thick sections were first19 paraffinized in

xylene and rehydrated in ethanol. The endogenous peroxidase activity was blocked (Ventana

Medical Systems, Tucson, Arizona, USA) before antigen retrieval was begun. The ULTRA

Cell Conditioning Solution (ULTRA CC1) from Ventana Medical Systems was then used for

antigen retrieval. Immunohistochemical staining was carried out on an automated

immunostainer, with primary antibody. This was followed by application of the avidin–biotin–

peroxidase complex technique. Reactions were developed with diamino-3,3′-benzidine

tetrahydrochloride substrate solution (SIGMAFAST; Sigma-Aldrich, Tucson, Arizona, USA).

The tissues were counterstained with hematoxylin. The primary antibodies and final dilutions

were: H3K27Me3 (Cell Signaling Technology, Danvers, Massachusetts, USA).

Immunostaining in the tumor tissue was determined by visual scoring of the brown stain. Scoring of the intensity of the staining was performed according to an arbitrary scale with steps of 0, 1, 2, and 3 where "0" was considered to be absence of staining, "1" considered weak staining, "2" was considered as moderately positive staining, and "3" was considered to be strong staining.

Statistics:

Statistical analyses were performed using GraphPad Prism (GraphPad Prism software version 9.5.0, San Diego, CA, USA). Descriptive statistics were used, and results are reported as mean, median, 2.5^{th}-25th-75th and 97.5^{th} percentiles. Data were subjected to Kolmogorov–Smirnov normality test. As data are not normally distributed, non-parametric methods were used: Mann-Whitney U test and Kruskal-Wallis H test for groups comparison and Spearman's rank correlation for measuring the dependence between variables. Significance values are represented by *: p-value < 0.05; **: $p < 0.01$; ***: $p < 0.001$; ****: $p < 0.0001$. Reference interval (also referred as normal range) of H3K27Me3-nucleosome levels was calculated on global healthy cohort to reach the statistically significant minimum number ($n \leq 120$). The data were subjected to D/R ratio and ROUT methods for the detection of outliers. Reference interval includes 95 % of the population, centred on the median. One standard deviation was added to the upper limit of this reference interval to determine the cut-off.

Study limitations:

As this is a retrospective study carried out for routine use, we are facing limitations, including: i) access to clinical data is limited to ctDNA molecular profile and time of sampling in the routine patient management; ii) we did not have matched tissue-plasma samples, the

histological analyses were performed with the commercial Tissue Macro-Array. iii)

independent cohorts were analyzed at diagnostic and during treatment.

DECLARATIONS

Ethics approval and consent to participate

Patients were recruited from the pulmonology department at Lyon University Hospital from

2015 to 2022 (Etude RNIPH 22-5065 NUCLEO_CIRCAN avis CSE n°22-5065).

Consent for publication

Medical data were collected through a mandatory prescription sheet and edited by the

prescribing physician. The patients were orally informed of the testing by physicians

conducting their clinical management.

Availability of data and materials

The data presented in this study are available in the Additional Files and from the

corresponding author: lea.payen-gay@chu-lyon.fr

Competing interests

J.C., N.H., R.R., G.R. and M.H. are employees of Belgian Volition SRL.

Funding

The authors thank AstraZeneca and Belgian Volition for financial support.

Authors' contributions

Conceptualization: E.G., D.B., M.H. and L.P.-G.; data curation: J.C., G.L., F.G., J.B. and

L.P.-G., formal analysis: E.G., J.C., D.B., M.H. and L.P.-G.; funding acquisition: S.C , and

L.P.-G; investigation: C.B., D.B., E.G., A.G., R.R and L.P.-G; methodology: F.S., D.B., G.L.,

N.H., M.H. and L.P.-G; project administration: C.R.-L., S.C., M.H. and L.P.-G.; resources:

S.C. and E.G.; supervision: M.H. and L.P-G.; validation: all authors; writing—original draft:

E.G., J.C., B.B., G.L., D.B., M.H. and L.P-G; writing-review and editing: J.C., B.B., G.L.,

D.B., A.-S.W., S.C., M.H. and L.P.-G. All authors have read and agreed to the published

version of the manuscript.

Acknowledgements

533   The authors are very grateful to AstraZeneca for their long-term collaboration with CIRCAN

534   team from Lyon-Sud Hospital. The authors thank AstraZeneca and Sysmex Inostics for their

535   continued financial support of this clinical study. The authors wish thanks the Assay

536   Development team from Belgian Volition for their technical support. We also thank Terry

537   Kelly for critical reading of the manuscript.

REFERENCES

1.   Fan HC, Blumenfeld YJ, Chitkara U, Hudgins L, Quake SR. Noninvasive diagnosis of fetal

aneuploidy by shotgun sequencing DNA from maternal blood. Proc Natl Acad Sci U S A.

2008;105(42):16266-71.

2.   Holdenrieder S, Stieber P, Chan LY, Geiger S, Kremer A, Nagel D, et al. Cell-free DNA in serum

and plasma: comparison of ELISA and quantitative PCR. Clin Chem. 2005;51(8):1544-6.

3.   Wimberger P, Roth C, Pantel K, Kasimir-Bauer S, Kimmig R, Schwarzenbach H. Impact of

platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and

disseminated tumor cells in bone marrow of ovarian cancer patients. Int J Cancer. 2011;128(11):2572-

80.

4.	Heitzer E, Auinger L, Speicher MR. Cell-Free DNA and Apoptosis: How Dead Cells Inform About

the Living. Trends Mol Med. 2020;26(5):519-28.

5.	Fernando MR, Jiang C, Krzyzanowski GD, Ryan WL. New evidence that a large proportion of

human blood plasma cell-free DNA is localized in exosomes. PLoS One. 2017;12(8):e0183915.

6.	Diaz LA, Jr., Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol.

2014;32(6):579-86.

7.	Fullgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene. 2011;30(31):3391-

403.

8.	Licht JD, Bennett RL. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clin

Epigenetics. 2021;13(1):115.

9.	Fenley AT, Anandakrishnan R, Kidane YH, Onufriev AV. Modulation of nucleosomal DNA

accessibility via charge-altering post-translational modifications in histone core. Epigenetics

Chromatin. 2018;11(1):11.

10.	Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat

Rev Genet. 2012;13(5):343-57.

11.	Zhao Z, Shilatifard A. Epigenetic modifications of histones in cancer. Genome Biol.

2019;20(1):245.

12.	Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The

polycomb group protein EZH2 is involved in progression of prostate cancer. Nature.

2002;419(6907):624-9.

13.	Comet I, Riising EM, Leblanc B, Helin K. Maintaining cell identity: PRC2-mediated regulation of

transcription and cancer. Nat Rev Cancer. 2016;16(12):803-10.

14.   Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al. EZH2 is a marker of aggressive

breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S

A. 2003;100(20):11606-11.

15.   Wiles ET, Selker EU. H3K27 methylation: a promiscuous repressive chromatin mark. Curr Opin

Genet Dev. 2017;43:31-7.

16.   Wan L, Li X, Shen H, Bai X. Quantitative analysis of EZH2 expression and its correlations with

lung cancer patients' clinical pathological characteristics. Clin Transl Oncol. 2013;15(2):132-8.

17.   Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, et al. PRC2 overexpression and

PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep.

2013;3:1911.

18.   Cardenas H, Zhao J, Vieth E, Nephew KP, Matei D. EZH2 inhibition promotes epithelial-to-

mesenchymal transition in ovarian cancer cells. Oncotarget. 2016;7(51):84453-67.

19.   Ma J, Zhang J, Weng YC, Wang JC. EZH2-Mediated microRNA-139-5p Regulates Epithelial-

Mesenchymal Transition and Lymph Node Metastasis of Pancreatic Cancer. Mol Cells. 2018;41(9):868-

80.

20.   Lachat C, Bruyere D, Etcheverry A, Aubry M, Mosser J, Warda W, et al. EZH2 and KDM6B

Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung

Carcinomas. Cancers (Basel). 2020;12(12).

21.   Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, et al. Regulation of tumor

angiogenesis by EZH2. Cancer Cell. 2010;18(2):185-97.

22.   Liu X, Lu X, Zhen F, Jin S, Yu T, Zhu Q, et al. LINC00665 Induces Acquired Resistance to Gefitinib

through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC. Mol Ther Nucleic Acids.

2019;16:155-61.

23.   Passaro A, Janne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung

cancer. Nat Cancer. 2021;2(4):377-91.

596 24. Gong H, Li Y, Yuan Y, Li W, Zhang H, Zhang Z, et al. EZH2 inhibitors reverse resistance to gefitinib

597 in primary EGFR wild-type lung cancer cells. BMC Cancer. 2020;20(1):1189.

598 25. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol.

599 2020;13(1):104.

600 26. Pennell NA, Arcila ME, Gandara DR, West H. Biomarker Testing for Patients With Advanced

601 Non-Small Cell Lung Cancer: Real-World Issues and Tough Choices. Am Soc Clin Oncol Educ Book.

602 2019;39:531-42.

603 27. Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical Utility of

604 Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly

605 Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019;25(15):4691-700.

606 28. Mack PC, Banks KC, Espenschied CR, Burich RA, Zill OA, Lee CE, et al. Spectrum of driver

607 mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis

608 of over 8000 cases. Cancer. 2020;126(14):3219-28.

609 29. Cui W, Milner-Watts C, McVeigh TP, Minchom A, Bholse J, Davidson M, et al. A pilot of Blood-

610 First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected

611 advanced lung cancer. Lung Cancer. 2022;165:34-42.

612 30. Kuang PP, Li N, Liu Z, Sun TY, Wang SQ, Hu J, et al. Circulating Tumor DNA Analyses as a

613 Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-

614 Cell Lung Cancer. Front Oncol. 2020;10:595650.

615 31. Nagasaka M, Uddin MH, Al-Hallak MN, Rahman S, Balasubramanian S, Sukari A, et al. Liquid

616 biopsy for therapy monitoring in early-stage non-small cell lung cancer. Mol Cancer. 2021;20(1):82.

617 32. Markou AN, Londra D, Stergiopoulou D, Vamvakaris I, Potaris K, Pateras IS, et al. Preoperative

618 Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary

619 Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.

620 Cancers (Basel). 2023;15(6).

621 33. Gale D, Heider K, Ruiz-Valdepenas A, Hackinger S, Perry M, Marsico G, et al. Residual ctDNA

622 after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann

623 Oncol. 2022;33(5):500-10.

624 34. Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early Detection of

625 Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov.

626 2017;7(12):1394-403.

627 35. Gong Y, Wei C, Cheng L, Ma F, Lu S, Peng Q, et al. Tracking the Dynamic Histone Methylation

628 of H3K27 in Live Cancer Cells. ACS Sens. 2021;6(12):4369-78.

629 36. Voigt P, Tee WW, Reinberg D. A double take on bivalent promoters. Genes Dev.

630 2013;27(12):1318-38.

631 37. Donaldson-Collier MC, Sungalee S, Zufferey M, Tavernari D, Katanayeva N, Battistello E, et al.

632 EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin

633 domains. Nat Genet. 2019;51(3):517-28.

634 38. Cai MY, Tong ZT, Zhu W, Wen ZZ, Rao HL, Kong LL, et al. H3K27me3 protein is a promising

635 predictive biomarker of patients' survival and chemoradioresistance in human nasopharyngeal

636 carcinoma. Mol Med. 2011;17(11-12):1137-45.

637 39. Haragan A, Field JK, Davies MPA, Escriu C, Gruver A, Gosney JR. Heterogeneity of PD-L1

638 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment

639 response. Lung Cancer. 2019;134:79-84.

640 40. Tsai CC, Chien MN, Chang YC, Lee JJ, Dai SH, Cheng SP. Overexpression of Histone H3 Lysine 27

641 Trimethylation Is Associated with Aggressiveness and Dedifferentiation of Thyroid Cancer. Endocr

642 Pathol. 2019;30(4):305-11.

643 41. Hoffmann F, Niebel D, Aymans P, Ferring-Schmitt S, Dietrich D, Landsberg J. H3K27me3 and

644 EZH2 expression in melanoma: relevance for melanoma progression and response to immune

645 checkpoint blockade. Clin Epigenetics. 2020;12(1):24.

42.   Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity

and a cause for therapy resistance? Nat Rev Cancer. 2013;13(5):365-76.

43.   Yuan S, Norgard RJ, Stanger BZ. Cellular Plasticity in Cancer. Cancer Discov. 2019;9(7):837-51.

44.   Li J, Stanger BZ. How Tumor Cell Dedifferentiation Drives Immune Evasion and Resistance to

Immunotherapy. Cancer Res. 2020;80(19):4037-41.

45.   Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, et al. Clinical

relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008;1137:180-9.

46.   Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients.

Nat Rev Cancer. 2011;11(6):426-37.

47.   McAnena P, Brown JA, Kerin MJ. Circulating Nucleosomes and Nucleosome Modifications as

Biomarkers in Cancer. Cancers (Basel). 2017;9(1).

48.   Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, et al. Circulating

nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung

cancer. Clin Cancer Res. 2004;10(18 Pt 1):5981-7.

49.   Barlesi F, Mazieres J, Merlio JP, Debieuvre D, Mosser J, Lena H, et al. Routine molecular

profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide

programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet. 2016;387(10026):1415-26.

50.   Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in

patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res. 2000;6(10):4055-63.

51.   Gu J, Zhou Y, Huang L, Ou W, Wu J, Li S, et al. TP53 mutation is associated with a poor clinical

outcome for non-small cell lung cancer: Evidence from a meta-analysis. Mol Clin Oncol. 2016;5(6):705-

13.

52.   Guo Y, Song J, Wang Y, Huang L, Sun L, Zhao J, et al. Concurrent Genetic Alterations and Other

Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A

Review. Front Oncol. 2020;10:610923.

53.   Assoun S, Theou-Anton N, Nguenang M, Cazes A, Danel C, Abbar B, et al. Association of TP53

mutations with response and longer survival under immune checkpoint inhibitors in advanced non-

small-cell lung cancer. Lung Cancer. 2019;132:65-71.

54.   Garcia J, Dusserre E, Cheynet V, Bringuier PP, Brengle-Pesce K, Wozny AS, et al. Evaluation of

pre-analytical conditions and comparison of the performance of several digital PCR assays for the

detection of major EGFR mutations in circulating DNA from non-small cell lung cancers: the CIRCAN_0

study. Oncotarget. 2017;8(50):87980-96.

55.   Bieler J, Pozzorini C, Garcia J, Tuck AC, Macheret M, Willig A, et al. High-Throughput Nucleotide

Resolution Predictions of Assay Limitations Increase the Reliability and Concordance of Clinical Tests.

JCO Clin Cancer Inform. 2021;5:1085-95.

56.   Garcia J, Gauthier A, Lescuyer G, Barthelemy D, Geiguer F, Balandier J, et al. Routine Molecular

Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at

Diagnosis and During Progression Using OncoBEAM(TM) EGFR V2 and NGS Technologies. Mol Diagn

Ther. 2021;25(2):239-50.

57.   Garcia J, Kamps-Hughes N, Geiguer F, Couraud S, Sarver B, Payen L, et al. Sensitivity, specificity,

and accuracy of a liquid biopsy approach utilizing molecular amplification pools. Sci Rep.

2021;11(1):10761.

FIGURES LEGEND

Figure 1. Quantification of circulating methylated-nucleosomes in NSCLC samples at

diagnosis and in healthy samples. The concentration of circulating H3K27Me3-, H3K36Me3-

, H3K9Me3- or H3K4Me2-nucleosomes were measured using chemiluminescent Nu.Q$^{®}$

immunoassays on human K2-EDTA plasma samples from NSCLC patients at diagnosis (DI)

and healthy donors. **A-B.** Box plot analysis representations circulating H3K27Me3-,

H3K36Me3, H3K9Me3 and H3K4Me2-nucleosome levels in NSCLC samples compared to

healthy samples in Training (A) and validation (B) sets. Boxes represent 25th-75th percentile

with median. Whiskers represent 2.5^{th}-97.5^{th} percentile. *** and **** represent *p*-value < 0.001

and < 0.0001, respectively, calculated by Mann-Whitney U test . **C-D.** Receiver-operating

characteristic (ROC) curve analysis of circulating H3K27Me3- and H3K4Me2-nucleosomes

for discrimination of NSCLC at diagnosis versus healthy samples in Training (C) and validation

sets (D). The areas under the curve (AUC) for the targeted nucleosome markers are indicated

in legend. The red line indicates the theoretical random chance. The corresponding significance

p-values for circulating H3K27Me3- and H3K4Me2-nucleosomes are respectively < 0.0001

and 0.0021 for the training set, *p* < 0.0001 and *p* = 0.0063 for the validation set.

Figure 2. Correlation between methylated-nucleosome levels, cfDNA concentration and

MAF percent in global NSCLC cohort at diagnosis. MAF % was given by SOPHIA DDM^{TM}

bio-informatics analysis and corresponds to ratio of the absolute count of read between mutated

forms on reference forms at each genomic position. Spearman's rank correlation coefficient

(Spearman's rho) was calculated for combinations represented in table. *** and **** represent

p-value < 0.001 and < 0.0001, respectively. The number of samples involved are indicated (n

=) for every correlation. Spearman's correlation coefficient ranges from 0 to 1 is represented

on the right panel as a color map.

Figure 3. Representative H3K27Me3 immunostaining (10x objective). (A) representative

image of normal lung tissue. **(B-D)** Representative images of weak (B), moderate (C) and high

(D) intensity immunostaining from lung adenocarcinoma. **(E)** H3K27Me3 expression in

function of grade.

Figure 4. Quantification of circulating H3K27Me3-nucleosomes in NSCLC at diagnosis and in healthy samples in whole cohorts. (A) Healthy samples (black) and NSCLC samples at diagnosis (DI) (white). **(B)** Healthy samples (black), NSCLC samples at DI in which somatic mutation was detected (ctDNA+; dot filled) or not (ctDNA-; white), according to the somatic molecular profile obtained with a panel of 78 genes containing the major oncodrivers known and in NSCLC samples at DI with mutated ctDNA detected. The boxes represent 25th-75th percentile with median. Whiskers represent 2.5^{th}-97.5^{th} percentile. *** and **** represent *p*-value < 0.001 and < 0.0001, calculated by Mann-Whitney (groups of interest (k) = 2) and Kruskal-Wallis (*k*>2) tests.

Figure 5. Decision tree proposed for the classification of NSCLC samples at Diagnosis. The decision is based on presence/absence of circulating tumor DNA (ctDNA) and on H3K27Me3-nucleosome levels below or above 22.5 ng/mL determined on K2-EDTA plasma samples from NSCLC patients at diagnosis. Number of samples (n =) are presented for the training (T; n = 203), the validation (V; n = 115) and the whole cohort (V+T; n = 318). Percentages express the part of the total cohort involved.

Figure 6. Quantification of circulating H3K27Me3-nucleosomes in NSCLC and healthy samples in the whole cohort during treatment. The concentration of circulating H3K27Me3-nucleosomes was measured using chemiluminescent Nu.Q® immunoassays on human K2-EDTA plasma samples from NSCLC patients during treatment (Tt) and from healthy donors. **A-B.** The box plot analyses representing circulating H3K27Me3-nucleosome levels **(A)** in NSCLC during treatment (white) compared with healthy samples (black). **(B)** or in NSCLC samples during treatment in which mutation is detected (ctDNA+; dot filled) or not (ctDNA-;

white), according to the somatic molecular profile obtained with a panel of 78 genes containing the major oncodrivers known in NSCLC. The boxes represent 25th-75th percentile with median. Whiskers represent 2.5th-97.5th percentile. *** and **** represent *p*-value < 0.001 and < 0.0001, calculated by Mann-Whitney (groups of interest (k) = 2) and Kruskal-Wallis (*k*>2) tests. **C.** Receiver-operating characteristic (ROC) curve analysis of circulating H3K27Me3-nucleosomes. Discrimination of NSCLC during treatment versus healthy groups (grey line) is compared to discrimination of NSCLC ctDNA+ during treatment versus healthy groups (black line) and to discrimination of NSCLC ctDNA- during treatment versus healthy groups (dotted line). The red line indicates the theoretical random chance. **D.** The groups size, areas under the curve (AUC) and corresponding *p*-values for the targeted groups are listed. All analyses are highly significant.

Figure 7. Decision tree proposed for the classification of NSCLC samples during patient follow-up. A. The decision is based on H3K27Me3-nucleosomes levels below or above 22.5 ng/mL and in presence/absence of circulating tumor DNA (ctDNA) determined on K2-EDTA plasma samples from NSCLC patients during treatment. Number of samples (n =) are presented for the whole cohort (W; n = 304). Percentages express the part of the total cohort involved. **B.** Biological and clinical interests are based on our proper interpretation and should be validated clinically.

Figure 8. H3K27Me3-nucleosome levels of NSCLC samples during treatment according to the somatic alteration status. The concentration of circulating H3K27Me3-nucleosomes was measured using chemiluminescent Nu.Q® immunoassays on human EDTA plasma samples. Only ctDNA+ group was included in this analysis. Minus (-) groups referred to

samples where a mutation in an oncodriver is different from the gene of interest (*EGFR*, *KRAS* or *TP53*); plus (+) groups referred to samples for which at least one mutation is detected in the gene of interest (*EGFR*, *KRAS* or *TP53*). **A.** Boxes represent 25th-75th percentile with median. Whiskers represent 2.5th-97.5th percentile. * represent *p*-value < 0.05 calculated by Mann-Whitney U test for testing the hypotheses of equality or difference between the two groups of interest. **B**. Groups size (n =) means and medians are summarized in table.

ADDITIONAL FILES

Fig. S1. A-B. ROC curve analyses of circulating H3K36Me3- and H3K9Me3-nucleosomes for discrimination of NSCLC versus healthy groups. The areas under the curve (AUC) for the targeted nucleosome markers are indicated in legend. The red line indicates the theoretical random chance. All curves were highly significantly different from the chance for circulating H3K36Me3- and H3K9Me3-nucleosomes and the *p*-value were all < 0.0001 for the training and validation sets.

Additional Figures.docx

Fig. S2. Frequencies distribution of H3K27Me3-nucleosome levels of healthy samples in training and validation sets. Training and validation sets are represented in white and grey bars, respectively. *y* axis represents the relative frequency of samples expressed in percent of the total cohort along the concentration of H3K27Me3 expressed in ng/mL on the *x* axis.

Additional Figures.docx

Table S1. Fold change between levels of methylated-nucleosomes in NSCLC at diagnosis compared to healthy samples. The fold change represents a ratio which is computed as the median level of specific circulating nucleosomes measured on NSCLC samples divided by the median level of the reference Healthy samples.

Table S1.xlsx

Table S2. A-B. Sensitivity and specificity data for the ROC curves in Figure 1 and 6. Data

corresponding to Figures 1 C and S1. A are presented in table S2 A (Training set); data corresponding

to Figures D and S1. B are presented in table S2 B (Validation set).

Table S2.xlsx

Table S3. Sensitivity and specificity data for the ROC curve in Figure 6C.

Table S3.xlsx

Fig. 1

Fig. 2

Spearman's *rho*	cfDNA		MAF	
H3K27me3	0,784	****	0,330	****
	n=311		n=315	
H3K36me3	0,661	****	0,310	****
	n=312		n=316	
H3K9me3	0,747	****	0,322	****
	n=312		n=316	
H3K4me2	0,527	****	0,214	****
	n=305		n=309	
cfDNA	/		0,284	***
			n=309	

Sig. (2-tailed) *p*-value : ***: $p < 0.001$; ****: $p < 0.0001$

Fig. 3

A

B. Weak staining

C. Moderate staining

D. Strong staining

E. H3K27Me3 immunostaining on Adenocarcinoma

Weak detection
Heterogenous detection
Strong detection

Chi^2 *p_value = 0.004*
Cramer's V = 39.4%

Fig. 4

Fig. 5

Non-Small Cell Lung Cancer at Diagnosis

Fig. 6

A

B

C

D

	H3K27Me3 in NSCLC Tt		
	All	ctDNA-	ctDNA+
Samples number (n)			
Healthy	201	201	201
All NSCLC Tt	304		
NSCLC Tt ctDNA-		173	
NSCLC Tt ctDNA+			131
ROC curve			
Area under the curve	0,7941	0,7359	0,8709
***p*_value**	< 0,0001	< 0,0001	< 0,0001

Fig. 7

Non-Small Cell Lung Cancer
After or during treatment

A

NSCLC during Treatment
Whole cohort (W) (n = 304)

ctDNA analysis
NGS

Absence of somatic alteration (ctDNA-)	Presence of somatic alteration (ctDNA+)
W (n = 173) 56,9%	W (n = 131) 43,1%

Circulating nucleosomes
Nu.Q° H3K27me3 assay

Circulating nucleosomes
Nu.Q° H3K27me3 assay

ctDNA - H3K27Me3 - - / - H3K27Me3 ≤ 22,5ng/mL W (n = 127) 41,8%	ctDNA - H3K27Me3 + - / + H3K27Me3 > 22,5ng/mL W (n = 46) 15,1%	ctDNA + H3K27Me3 - + / - H3K27Me3 ≤ 22,5ng/mL W (n = 59) 19,4%	ctDNA + H3K27Me3 + + / + H3K27Me3 > 22,5ng/mL W (n = 72) 23,7%

B

Biological interest

No circulating tumoral material detected	Circulating tumoral material detected

Clinical interest

Continue with first line treatment	Change treatment to classic second line therapy Consider combined therapy with EZH2-inhibitor

Fig. 8

A

B

		H3K27me3 (ng/mL)	
	n =	mean	median
NSCLC during or after treatment	304	67,29	16,89
ctDNA-	173	31,98	13,35
ctDNA+	131	113,92	26,05
EGFR-	53	101,91	34,08
EGFR+	78	122,09	20,69
KRAS-	124	115,30	26,70
KRAS+	7	90,00	14,80
TP53-	72	97,50	19,20
TP53+	59	134,00	36,90